About Us

THIS IS PERSONAL

Our founders have asthma, and had acute episodes of exacerbations throughout childhood and growing up. Built by patients, clinicians, and engineers, Vigor is the future of respiratory care to them for the digital era.

LUNG HEALTH IS REAL

Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) afflict more than 600 million people worldwide and kill more than 3.5 million people each year. Infectious respiratory diseases have caused 4 global health crises since 2000, and there is a long road to recovery for millions with Covid-19. Besides heart disease and stroke, respiratory diseases are the leading causes of mortality worldwide.

LUNG CONDITIONS ARE POORLY DIAGNOSED AND MANAGED

Pulmonary function testing, also known as spirometry, is the “gold standard” for the diagnosis and management of chronic respiratory conditions. However, such equipment is often found only in large hospitals and specialist clinics, can range from the size of a desktop to a refrigerator, and cost between USD 3,000 to USD 20,000. This is impractical for many around the world, leading to massive under-diagnosed populations and sub-optimal care. Unlike diabetes and heart disease, home-based management of respiratory diseases remains in the analog era, lacking connectivity, coordination, and integration.

VIGOR MEETS URGENT GLOBAL NEEDS

Our team blends decades of clinical, commercial, and product development expertise in both startups (5x exits) and the largest healthcare companies with award-winning technologists who specialize in AI and digital health. Our advisors include leading KOLs in pulmonary medicine, behavioral science, and health systems in different regions. With patented technology invented at Duke University, Vigor is headquartered in the USA, partnered globally with Johnson & Johnson Innovation / JLABS, and operating globally to meet your needs.